Bionano Genomics (NASDAQ: BNGO), a pioneer of optical genome mapping solutions, has announced second quarter results that included 73% year-over-year revenue growth as well as a 24% increase in sales of its nanochannel array flowcells.

The company also launched version 6.2 of its NxClinical software that includes integrated genomic scar analysis for homologous recombination deficiency. The new feature provides a comprehensive, consistent, and automated analysis of biomarkers from next-generation sequencing and microarray data that can help clinical researchers stratify therapeutic response across multiple tumor types.

During the second quarter the company also announced a new collaboration agreement with Hamilton to develop the Long String VANTAGE for isolation of Ultra High Molecular Weight DNA for use in optical genome mapping. The company believes this workflow has the potential to double manual output, with increased confidence in sample yields and DNA quality.

Erik Holmlin, President and CEO of Bionano commented: “We believe our Q2 2022 results, which include record quarterly revenues for Bionano, show that the foundation we laid in 2021 has carried us into 2022 and that the great progress demonstrated by this quarter’s growth in Saphyr system installed base reflects continued gains in market development and proof of concept.”

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software

Shares of Bionano Genomics trade on the NASDAQ under the ticker symbol BNGO.